OPEC+ Oil Hikes Pressure Brent, Novartis Acquires Myricx in $1.5B Deal, and U.S. Manufacturing PMI Eases to 53.3%

The first full trading week of July 2026 delivered three stories at the intersection of energy geopolitics, pharmaceutical M&A, and macroeconomic data — each with distinct investment implications. OPEC+'s fifth consecutive monthly output increase (+188,000 bpd for August) drove Brent below $72/bbl — a reversal from $84.80/bbl at the June escalation peak — marking the fastest single-month oil price deflation since November 2023, and a direct tailwind for global headline CPI in Q3. Novartis's $1.5B acquisition of Myricx Bio (NMT inhibitor ADC payload platform, spun out of Imperial College London + Francis Crick Institute in 2019) is the 4th ADC-focused acquisition by a large-cap pharma in 2026, confirming that the ADC modality war is the defining M&A theme of 2026 biotech. And the ISM Manufacturing PMI at 53.3% (6th consecutive month above 50) — alongside a cooling Prices Paid sub-index — gives the Fed the macro backdrop it needs to hold rates without hikes, while the falling Prices Paid index indicates supply-chain input cost pressures are genuinely abating.

---

📈 OPEC+ Fifth Consecutive Output Hike — Brent Below $72

The Phased Unwinding Mechanics and Market Impact

OPEC+ 2024–2026 production discipline timeline:

The July 5 announcement — 7 OPEC+ core members:

Kazakhstan and Iraq compliance risk: Kazakhstan has consistently exceeded its quota since 2023 due to Tengiz field expansion (Chevron JV). June 2026 overproduction: ~180,000 bpd above quota. Iraq: ~130,000 bpd above quota in June. Combined overproduction = 310,000 bpd — partially offsetting the "official" production target restraint.

Why $71.70 — the price anatomy:

The inflation tailwind — why this matters for central banks: Brent falling from $84.80 (June peak) to $71.70 (July 6) = −15.5% in ~3 weeks. Impact chain:

• Gasoline prices: US average retail gasoline falls ~$0.08–0.10/gallon for every $5/bbl oil decline → −$0.24–0.30/gallon decline
• US headline CPI impact: Gasoline is ~3.5% of CPI basket → −$13/bbl oil = approximately −0.15% to CPI contribution
• Timeline: Oil price changes feed into CPI with a 4–6 week lag via retail pump prices and then transport/food prices
• October CPI implication: If Brent holds at $72–75, October CPI could fall to 3.1–3.2% vs current 3.5% — approaching the range that gives Fed more confidence to cut

OPEC+ August 2026 advisory meeting: The next ministerial monitoring meeting is scheduled for August 2, 2026. Key variables:

1. Brent below $70: OPEC+ would likely pause or reverse the unwind — Saudi fiscal breakeven is $80/bbl
2. Brent $70–78: Continue +188K bpd/month increases as planned
3. Brent above $82: Accelerate unwind by adding further members to the release programme

---

🧬 Novartis Acquires Myricx Bio — The ADC Platform Wars

$1.5B for NMT Inhibitor Technology from Imperial College and the Crick Institute

Myricx Bio profile:

The NMT inhibitor (NMTi) — why it's a breakthrough payload: ADC (Antibody-Drug Conjugate) structure: Antibody (targeting) + Linker + Payload (cytotoxin). The payload determines therapeutic window and tolerability.

Traditional ADC payloads:

• Topoisomerase-1 inhibitors (DXd — used in Enhertu/trastuzumab deruxtecan): Mechanism = DNA damage. Risk: bone marrow toxicity at high doses.
• Tubulin inhibitors (MMAE — used in Padcev, Adcetris): Mechanism = cell division arrest. Risk: peripheral neuropathy.

NMTi payload — Myricx's innovation:

The key advantage: as more ADCs enter the market with DXd and MMAE payloads, patients develop resistance to those payload mechanisms. A completely orthogonal payload mechanism (NMTi) offers retreatment options for resistant patients — a significant unmet need.

The 2026 ADC M&A landscape — Novartis in context:

Novartis's existing ADC position: Novartis's ADC portfolio before Myricx:

• Lutathera (Lu-DOTATATE): Radioligand therapy (RLT), not traditional ADC — neuroendocrine tumours
• Kisqali + Kymriah: Not ADCs
• Pipeline ADC: NJH395 (anti-CD19 DXd ADC) — early Phase I

Myricx transforms Novartis from "ADC follower" to "payload technology owner" — instead of licensing DXd (from Daiichi Sankyo) or MMAE (from Seattle Genetics), Novartis will own its own payload platform, enabling internal ADC discovery without royalty burden.

Brandon Capital, Sofinnova, and Novo Holdings exit: The three institutional backers collectively invested ~$95M across Myricx's seed through Series B rounds. The $1.1B upfront creates approximately 11.6× return on invested capital (ROIC) for the syndicate — one of the strongest biotech exit multiples in European VC in 2026.

---

📊 ISM Manufacturing PMI at 53.3% — Soft Landing Confirmed?

What the Sub-Indices Reveal About the US Economy

ISM Manufacturing PMI — 6 consecutive months above 50:

The critical Prices Paid sub-index — the inflation signal: Prices Paid fell from 59.1 (May) to 56.2 (June) — a 2.9-point decline. Context:

• Prices Paid above 60: Inflationary pressure building (manufacturers paying more for inputs)
• Prices Paid 56.2: Prices paid rising but at a slower rate — consistent with continued goods disinflation
• Prices Paid correlation with Producer Price Index (PPI) with 1-month lead: the June drop suggests July PPI will come in soft

What the 6-month expansion run means for recession risk: Historical pattern: US manufacturing PMI below 47 for 6+ months = recession within 12 months (correlation: 76% since 1970). Conversely, PMI above 52 for 6+ months = no recession in following 12 months (correlation: 91%). At 53.3 × 6 months = recession risk extremely low by historical standards.

The Employment Index — the nuance: The Employment sub-index showed "minor contraction" (below 50). Manufacturing employment is falling slightly even as manufacturing output is growing → productivity gains. This is the "jobless recovery" pattern in manufacturing:

• AI/automation investments allow manufacturers to increase output without proportional headcount
• Example: Boeing 737 MAX production rate increased 12% in Q1 2026 with 3% fewer assembly workers (automation of fuselage joining)

The US PMI vs Eurozone PMI divergence:

The US-Eurozone divergence (53.3 vs 45.5 = 7.8-point gap) is at its widest since 2014. This gap is the primary driver of USD strength — investors are allocating capital to US assets where industrial activity is growing, away from European assets where it is contracting.

---

📌 The Bottom Line

• opec-188k-bpd-august-brent-71-70-5th-consecutive-hike-phased-unwinding: 5th consecutive output increase (+188K bpd) from 7 core OPEC+ members (Saudi, Russia, Iraq, Kuwait, Kazakhstan, Algeria, Oman); Brent $84.80 (June peak) → $71.70 (July 6) = −15.5% in 3 weeks; Kazakhstan +180K + Iraq +130K = 310K over-quota = actual release partially offset; Brent anatomy: $65-67 fundamental + $4-5 OPEC premium + $1-2 residual geopolitical = $71.70; −$13/bbl oil = −0.15pp CPI → October CPI could fall to 3.1-3.2% if sustained; OPEC+ August 2 meeting: pause trigger <$70, continue trigger $70-78, accelerate trigger >$82.
• novartis-myricx-bio-1-5b-adc-nmti-payload-imperial-crick-spinout: Myricx: 2019 spinout from Imperial College London + Francis Crick Institute; NMTi payload = completely orthogonal to DXd (Topo-1) and MMAE (tubulin) = no cross-resistance = retreatment for resistant patients; key assets: NMTi-ADC targeting B7-H3 (solid tumours) + HER2 (breast/gastric); $1.1B upfront + $400M milestones; 2026 ADC M&A wave: Roche ($1.5B), AstraZeneca ($2.4B), Pfizer ($43B 2023) + Novartis ($1.5B); Novartis strategic shift: payload licensor → payload owner (no DXd royalties); Brandon+Sofinnova+Novo Holdings: ~$95M invested → ~11.6× ROIC on $1.1B cash.
• ism-manufacturing-pmi-53-3-6th-month-expansion-soft-landing: ISM 53.3% in June (6th consecutive above 50 = historical 91% no-recession correlation in following 12 months); Prices Paid 59.1→56.2 (−2.9pts = goods disinflation continues; leads PPI by 1 month → July PPI soft); Employment sub-index < 50 (productivity gain: more output, fewer workers = AI/automation effect); New Orders 54.3 (solid = demand pipeline robust); US-Eurozone gap: 53.3 vs 45.5 = 7.8pts = widest since 2014 (primary USD strength driver); Germany 43.2 = severe industrial recession while US grows.

---

📬 Stay Updated

Get global market analysis delivered to your inbox every week. Subscribe to our free newsletter →

---

Disclosure: This post contains affiliate links. If you purchase through our links, we earn a small commission at no extra cost to you. We only recommend products we believe in.